Dentons (Paris and London) has assisted Théa Open Innovation with the signature of a partnership agreement with Link Biologics, including an equity investment from Théa Open Innovation, to develop Link_TSG6, a biologic drug for Dry Eye Disease (DED) worldwide (excluding Asia). Link_TSG6 is a biological drug based on human TSG-6, a protein that plays an intrinsic role to protect tissues from inflammatory damage.
Link Biologics will be responsible for all DED research and development up to the end of Phase 2 trials, with Théa Open Innovation taking over responsibilities, including commercialization of the drug thereafter.
This partnership is in line with Théa Group’s mission to provide cutting-edge ophthalmic solutions to eye care specialists and patients alike. Théa Open Innovation is a sister company of Laboratoires Théa. Its role is to identify, evaluate and support the most innovative development in eye care, throughlicensing agreements and/or equity investments.
The Dentons team was led by Jean-Marc Grosperrin (Partner), with Emmanuelle De Schepper (Of Counsel), (both Corporate) in Paris, and Neil Nicholson (Partner), Christopher Winn (Senior Associate) and Arjun Mehta (Associate) (all Corporate) in London.
